Skip to main content

Table 3 Univariate and multivariate analysis of OS

From: Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice

Variable (comparator)Overall survival
Univariate analysisMultivariate analysis
HR (95% CI)p-valueHR (95% CI)p-value
Early ir-fatigue
 Yes vs no2.63 (1.83–3.77)< 0.00012.32 (1.59–3.38)< 0.0001
Sex
 Male vs female1.41 (0.97–2.05)0.0669
Age at diagnosis
 Elderly vs non-elderly1.35 (0.96–1.89)0.0758
Primary tumor (melanoma)
 NSCLC2.24 (1.52–3.28)< 0.00011.72 (1.14–2.60)0.0095
 Renal cell carcinoma1.62 (0.99–2.63)0.05181.40 (0.82–2.37)0.2101
 Others0.74 (0.10–5.38)0.76790.58 (0.07–4.29)0.5992
Treatment line
 Non-first vs first1.58 (1.08–2.31)0.01701.33 (0.88–2.01)0.1717